
    
      The study is designed to evaluate safety and efficacy of ATH-1017 in mild to moderate AD
      subjects, with double-blind, parallel-arm treatment duration of 26 weeks, and based on
      clinical diagnostic criteria of Alzheimer's disease. Clinical efficacy is demonstrated by
      improvement in cognition and global/functional assessments comparing treatment to placebo.
    
  